Breast Cancer Metastasis and Drug Resistance
Springer International Publishing (Verlag)
978-3-030-20300-9 (ISBN)
Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Expertsalso discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.
Aamir Ahmad, PhD, is Assistant Professor of Oncologic Sciences at University of South Alabama's Mitchell Cancer Institute, Mobile, AL, USA. He received his academic degrees from AMU, Aligarh, India and completed post-doctoral training at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. His research interests include understanding the mechanisms of cancer drug resistance and metastasis in different cancers, with emphasis on the role of microRNAs, non-coding RNAs, epigenetics, exosomes, cancer stem cells and a personalized approach. He has authored 160 scientific research / review articles, edited/co-edited 8 books and serves as Expert Reviewer for scientific proposals submitted to 8 different funding agencies in Europe, Asia and Africa. He is the Founding Editor-in-Chief of the journal "Non-coding RNA Research", Section Editor for the journal "Scientific Reports", and is Section Editor for the journal "PLoS ONE". He is also the Editor-in-Chief of the Elsevier series 'Cancer Metastasis'.
Chaper 1: Breast Cancer Statistics: Recent trends.- Chapter 2: Epidemiology of Breast Cancer in Women.- Chapter 3: Health and Racial Disparity in Breast Cancer.- Chapter 4: Breast Cancer: Current perspectives on the disease status.- Chapter 5: Role of Autophagy in Breast Cancer Development and Progression: Opposite Sides of the Same Coin.- Chapter 6: Breast Cancer Heterogeneity in Primary and Metastatic Disease.- Chapter 7: Bone Metastasis of Breast Cancer.- Chapter 8: Therapeutic Options for Metastatic Breast Cancer.- Chapter 9: Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment.- Chapter 10: Current Updates on Trastuzumab Resistance in HER2 overexpressing Breast Cancers.- Chapter 11: Non-coding RNAs as mediators of tamoxifen resistance in breast cancers.- Chapter 12: TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome DrugResistance.- Chapter 13: Current state of platinum complexes for the treatment of advanced and drug-resistant breast cancers.- Chapter 14: Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance.- Chapter 15: Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and its Partners to Overcome Metastasis and Drug Resistance.- Chapter 16: Epigenetics of Breast Cancer: Clinical Status of Epi-Drugs and Phytochemicals.- Chapter 17: Targeting CSC in a most aggressive subtype of breast cancer TNBC.- Chapter 18: Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability.- Chapter 19: NEDD4 Family of E3 Ubiquitin Ligases in Breast Cancer: Spotlight on SMURFs, WWPs and NEDD4.- Chapter 20. Emerging Novel Therapeutics in Triple-Negative Breast Cancer.- Chapter 21.Breast Cancer: Proteolysis and Migration.- Chapter 22: Current and emerging 3D models to study breast cancer.
| Erscheinungsdatum | 07.09.2019 |
|---|---|
| Reihe/Serie | Advances in Experimental Medicine and Biology |
| Zusatzinfo | XVIII, 427 p. 60 illus., 51 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 789 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Medizin / Pharmazie ► Studium | |
| Schlagworte | antibacterial drug resistance • bone metastasis • breast cancer statistics • breast cancer stem cells • Tamoxifen • triple negative breast cancer |
| ISBN-10 | 3-030-20300-X / 303020300X |
| ISBN-13 | 978-3-030-20300-9 / 9783030203009 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
